News
Aikido Pharma Focuses on The Treatment of Four Main Types of Cancer
Aikido Pharma Inc is a biotechnology development company working to develop a diverse portfolio of early and mid-stage small-molecule anti-cancer therapeutics. Our diverse pipeline of therapeutics includes therapies for prostate, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Our prostate and pancreatic treatment has shown positive preclinical results. For more information, get in touch with Aikido Pharma Inc by calling us at 212-745-1373.
Our platform contains patented technology from leading universities and researchers and we seek to develop our innovative drugs through strong partnership with world renowned institutions, such as The University of Texas and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Our prostate and pancreatic treatment has shown positive preclinical results.
For more information, you can visit our website to learn about the individual treatment and associated research on the drugs that have been developed to treat prostate, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Get in touch with us today by calling 212-745-1373,
More News
Aikido Pharma Has Licensed DHA-dFdC at The University of Texas at Austin
Aikido Pharma Has Licensed DHA-dFdC at The University of Texas at Austin
Released On: 3/5/2021
Views: 795
Aikido Pharma Shares Published Papers and Articles on KPC-34 and DHA-dFdC
Aikido Pharma Shares Published Papers and Articles on KPC-34 and DHA-dFdC
Released On: 3/3/2021
Views: 770
Aikido Pharma Announces Findings of Positive Results From New Drug “DHA-dFdC” Developed at The University of Texas at Austin
Aikido Pharma Announces Findings of Positive Results From New Drug “DHA-dFdC” Developed at The University of Texas at Austin
Released On: 3/1/2021
Views: 811
AIkido Pharma Inc. to Present at the H.C. Wainwright Global Life Sciences Conference (Virtual Event)
AIkido Pharma Inc. to Present at the H.C. Wainwright Global Life Sciences Conference (Virtual Event)
Released On: 3/1/2021
Views: 1198
Meet Aikido Pharma Inc’s Board of Directors
Meet Aikido Pharma Inc’s Board of Directors
Released On: 2/28/2021
Views: 815
AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering
AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering
Released On: 2/23/2021
Views: 856
Artificial Intelligence Is Optimizing Drug Development
Artificial Intelligence Is Optimizing Drug Development
Released On: 2/22/2021
Views: 864
Aikido Pharma Focuses on The Treatment of Four Main Types of Cancer
Aikido Pharma Focuses on The Treatment of Four Main Types of Cancer
Released On: 2/20/2021
Views: 757
AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock
AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock
Released On: 2/19/2021
Views: 921
AIkido Pharma Inc. Increases Previously Announced Bought Deal Offering of Common Stock to $75 Million
AIkido Pharma Inc. Increases Previously Announced Bought Deal Offering of Common Stock to $75 Million
Released On: 2/16/2021
Views: 1015
AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock
AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock
Released On: 2/16/2021
Views: 964
AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment
AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment
Released On: 2/16/2021
Views: 1077
Aikido Pharma Announces Information on KPC-34 Which Was Developed at the Wake Forest School of Medicine
Aikido Pharma Announces Information on KPC-34 Which Was Developed at the Wake Forest School of Medicine
Released On: 2/15/2021
Views: 767
Aikido Pharma Establishes Licensing Agreement with University of Maryland for Antiviral Compounds, Including COVID-19
Aikido Pharma Establishes Licensing Agreement with University of Maryland
for Antiviral Compounds, Including COVID-19
Released On: 2/10/2021
Views: 682
Aikido Pharma Announces DHA-dFdC Which Is Licensed From the University of Texas at Austin for the treatment of Pancreatic Cancer.
Aikido Pharma Announces DHA-dFdC Which Is Licensed From the University of Texas at Austin for the treatment of Pancreatic Cancer.
Released On: 2/9/2021
Views: 1250
Aikido Pharma Secures Early Interest in Convergent Therapeutics, Inc. Who Focuses On Next Generation Radiopharmaceutical Therapy for Prostate Cancer
Aikido Pharma Secures Early Interest in Convergent Therapeutics, Inc. Who Focuses On Next Generation Radiopharmaceutical Therapy for Prostate Cancer
Released On: 2/5/2021
Views: 836
AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board
AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board
Released On: 2/3/2021
Views: 1700
Meet Aikido Pharma A BioTechnology Development Company Focused on The Treatment Of Early and Mid-Stage Small-Molecule Anti-Cancer Therapeutics
Meet Aikido Pharma A BioTechnology Development Company Focused on The Treatment Of Early and Mid-Stage Small-Molecule Anti-Cancer Therapeutics
Released On: 2/3/2021
Views: 920
Map
Aikido Pharma
Get DirectionsAikido Pharma
-
One Rockefeller Plaza
New York, New York 10020
United States - (212) 745-1373
